Results 301 to 310 of about 1,056,606 (342)
Some of the next articles are maybe not open access.
New England Journal of Medicine, 2015
SCOPUS: le.j ; info:eu-repo/semantics ...
Vandergheynst, Frederic +2 more
openaire +4 more sources
SCOPUS: le.j ; info:eu-repo/semantics ...
Vandergheynst, Frederic +2 more
openaire +4 more sources
The Lancet, 1999
The very potent endogenous vasoconstrictor endothelin was discovered in 1988. We know now that there are three isoforms (1, 2, and 3) and two receptor subtypes (A and B). A whole range of peptide and non-peptide antagonists has been developed, some selective for A or B receptors and others with non-selective A/B antagonistic activity.
A, Benigni, G, Remuzzi
openaire +2 more sources
The very potent endogenous vasoconstrictor endothelin was discovered in 1988. We know now that there are three isoforms (1, 2, and 3) and two receptor subtypes (A and B). A whole range of peptide and non-peptide antagonists has been developed, some selective for A or B receptors and others with non-selective A/B antagonistic activity.
A, Benigni, G, Remuzzi
openaire +2 more sources
Progress in Cardiovascular Diseases, 2004
Calcium antagonists were introduced for the treatment of hypertension in the 1980s. Their use was subsequently expanded to additional disorders, such as angina pectoris, paroxysmal supraventricular tachycardias, hypertrophic cardiomyopathy, Raynaud phenomenon, pulmonary hypertension, diffuse esophageal spasms, and migraine.
Ehud, Grossman, Franz H, Messerli
openaire +2 more sources
Calcium antagonists were introduced for the treatment of hypertension in the 1980s. Their use was subsequently expanded to additional disorders, such as angina pectoris, paroxysmal supraventricular tachycardias, hypertrophic cardiomyopathy, Raynaud phenomenon, pulmonary hypertension, diffuse esophageal spasms, and migraine.
Ehud, Grossman, Franz H, Messerli
openaire +2 more sources
Molecular Diversity, 2008
CCR1 (CC Chemokine receptor 1) is a widely studied G protein-coupled receptor target expressed on multiple types of leukocytes. It is implicated in initiating and exacerbating inflammatory conditions and thus is viewed as a good target for autoimmune and inflammatory therapeutic applications. Numerous CCR1 antagonists have been reported.
Jie-Fei, Cheng, Rick, Jack
openaire +2 more sources
CCR1 (CC Chemokine receptor 1) is a widely studied G protein-coupled receptor target expressed on multiple types of leukocytes. It is implicated in initiating and exacerbating inflammatory conditions and thus is viewed as a good target for autoimmune and inflammatory therapeutic applications. Numerous CCR1 antagonists have been reported.
Jie-Fei, Cheng, Rick, Jack
openaire +2 more sources
Cardiology, 1985
At present nitrates remain the initial treatment for relief or prevention of angina in patients with coronary artery disease. In cases where nitrates and beta blockers have been used and are ineffective for managing effort angina, calcium antagonists may be substituted or added to the beta-blocking treatment. When the predominant symptom is rest angina,
C R, Conti +3 more
openaire +2 more sources
At present nitrates remain the initial treatment for relief or prevention of angina in patients with coronary artery disease. In cases where nitrates and beta blockers have been used and are ineffective for managing effort angina, calcium antagonists may be substituted or added to the beta-blocking treatment. When the predominant symptom is rest angina,
C R, Conti +3 more
openaire +2 more sources
Expert Opinion on Biological Therapy, 2001
The majority of cancer have an absolute requirement for angiogenesis, the process by which new blood vessels are formed. The most potent angiogenic cytokine is vascular endothelial growth factor (VEGF) and there has been substantial research into the development of VEGF/VEGF receptor (VEGFR) antagonists.
Hasan, J, Jayson, G
openaire +3 more sources
The majority of cancer have an absolute requirement for angiogenesis, the process by which new blood vessels are formed. The most potent angiogenic cytokine is vascular endothelial growth factor (VEGF) and there has been substantial research into the development of VEGF/VEGF receptor (VEGFR) antagonists.
Hasan, J, Jayson, G
openaire +3 more sources
Current Topics in Medicinal Chemistry, 2010
Inhibition of CCR2 has been considered as a target for multiple therapeutic diseases including autoimmune disease, atherosclerosis, pain, and metabolic disease, based in part on the critical role this receptor plays on monocyte migration. Numerous companies have reported programs to identify CCR2 antagonists.
Mary, Struthers, Alexander, Pasternak
openaire +2 more sources
Inhibition of CCR2 has been considered as a target for multiple therapeutic diseases including autoimmune disease, atherosclerosis, pain, and metabolic disease, based in part on the critical role this receptor plays on monocyte migration. Numerous companies have reported programs to identify CCR2 antagonists.
Mary, Struthers, Alexander, Pasternak
openaire +2 more sources
Clinics in Liver Disease, 2003
Hepatotoxicity is the most common cause of fulminant hepatic failure in the United States and the main indication for market withdrawal of drugs. This condition has been increasingly recognized as a problem of enormous medical, financial legal, and regulatory importance.
Timothy J, Davern, Nathan M, Bass
openaire +2 more sources
Hepatotoxicity is the most common cause of fulminant hepatic failure in the United States and the main indication for market withdrawal of drugs. This condition has been increasingly recognized as a problem of enormous medical, financial legal, and regulatory importance.
Timothy J, Davern, Nathan M, Bass
openaire +2 more sources